Stock listing
OTC:NWBO Northwest Biotherapeutics, Inc. Stock
Follow Northwest Biotherapeutics, Inc. into a list and get an email when it puts out news.
Share price · OTC:NWBO
$0.129 USD -0.016 (-11.1%)
Close on Nov 20, 2026
- Day range
- $0.122 – $0.139 USDNov 20, 2026
- Volume
- 2.29M sharesNov 20, 2026
- Market cap
- $220.0M USDAt the close on Nov 20, 2026 · price × 1.71B shares outstanding
- 52-week range
- $0.122 – $0.340 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $630,668 USDMedian day 2.65M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:NWBO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.129 | -0.016 | -11.1% | $0.135 | $0.139 | $0.122 | 2,291,092 | |
| $0.145 | -0.002 | -1.3% | $0.153 | $0.157 | $0.145 | 1,266,072 | |
| $0.147 | +0.001 | +0.5% | $0.148 | $0.153 | $0.138 | 3,462,853 | |
| $0.146 | -0.009 | -5.9% | $0.155 | $0.155 | $0.145 | 1,503,737 | |
| $0.155 | -0.012 | -7.4% | $0.166 | $0.166 | $0.155 | 2,336,022 | |
| $0.168 | -0.001 | -0.4% | $0.170 | $0.171 | $0.164 | 1,257,156 | |
| $0.168 | +0.001 | +0.8% | $0.168 | $0.168 | $0.164 | 739,706 | |
| $0.167 | +0.001 | +0.7% | $0.168 | $0.168 | $0.166 | 723,190 | |
| $0.166 | -0.001 | -0.6% | $0.169 | $0.169 | $0.163 | 2,160,055 | |
| $0.167 | +0.002 | +1.3% | $0.169 | $0.170 | $0.163 | 1,917,976 | |
| $0.165 | 0.000 | -0.1% | $0.170 | $0.171 | $0.160 | 3,631,484 | |
| $0.165 | -0.003 | -1.8% | $0.169 | $0.185 | $0.157 | 4,273,163 | |
| $0.168 | -0.008 | -4.5% | $0.175 | $0.176 | $0.168 | 887,107 | |
| $0.176 | +0.006 | +3.5% | $0.170 | $0.177 | $0.160 | 658,946 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.180 | $0.170 | 3,044,800 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.170 | $0.170 | 3,931,900 | |
| $0.170 | +0.010 | +6.3% | $0.160 | $0.170 | $0.160 | 2,277,600 | |
| $0.160 | -0.010 | -5.9% | $0.170 | $0.170 | $0.160 | 5,861,900 | |
| $0.170 | +0.020 | +13.3% | $0.150 | $0.170 | $0.150 | 7,525,400 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.160 | $0.150 | 5,487,100 | |
| $0.150 | -0.020 | -11.8% | $0.170 | $0.170 | $0.150 | 4,593,600 | |
| $0.170 | +0.010 | +6.3% | $0.160 | $0.170 | $0.160 | 6,510,200 | |
| $0.160 | 0.000 | 0.0% | $0.160 | $0.170 | $0.150 | 5,902,200 | |
| $0.160 | 0.000 | 0.0% | $0.160 | $0.160 | $0.150 | 4,291,500 | |
| $0.160 | +0.010 | +6.7% | $0.160 | $0.160 | $0.150 | 3,915,700 | |
| $0.150 | -0.010 | -6.3% | $0.160 | $0.170 | $0.150 | 4,430,800 | |
| $0.160 | 0.000 | 0.0% | $0.170 | $0.170 | $0.160 | 5,334,800 | |
| $0.160 | 0.000 | 0.0% | $0.160 | $0.170 | $0.160 | 6,752,500 | |
| $0.160 | 0.000 | 0.0% | $0.170 | $0.180 | $0.160 | 18,208,100 | |
| $0.160 | +0.010 | +6.7% | $0.160 | $0.170 | $0.150 | 19,062,800 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.160 | $0.140 | 5,582,200 | |
| $0.150 | 0.000 | 0.0% | $0.140 | $0.150 | $0.140 | 3,906,300 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.140 | 3,909,900 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.140 | 2,499,100 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.160 | $0.150 | 1,512,800 | |
| $0.150 | 0.000 | 0.0% | $0.140 | $0.150 | $0.140 | 1,537,900 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.140 | 3,438,300 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.160 | $0.150 | 4,896,500 | |
| $0.150 | -0.010 | -6.3% | $0.160 | $0.160 | $0.150 | 3,918,100 | |
| $0.160 | 0.000 | 0.0% | $0.160 | $0.160 | $0.160 | 2,348,200 | |
| $0.160 | 0.000 | 0.0% | $0.160 | $0.170 | $0.160 | 2,391,500 | |
| $0.160 | 0.000 | 0.0% | $0.160 | $0.160 | $0.160 | 2,443,600 | |
| $0.160 | -0.010 | -5.9% | $0.170 | $0.170 | $0.160 | 2,778,200 | |
| $0.170 | +0.010 | +6.3% | $0.160 | $0.170 | $0.160 | 4,581,300 | |
| $0.160 | -0.010 | -5.9% | $0.170 | $0.170 | $0.160 | 4,589,700 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.170 | $0.160 | 1,260,900 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.180 | $0.160 | 1,941,500 | |
| $0.170 | +0.010 | +6.3% | $0.170 | $0.170 | $0.170 | 1,814,900 | |
| $0.160 | -0.010 | -5.9% | $0.170 | $0.170 | $0.160 | 1,449,800 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.170 | $0.160 | 1,207,100 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.170 | $0.170 | 880,600 | |
| $0.170 | 0.000 | 0.0% | $0.180 | $0.180 | $0.170 | 2,650,300 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.170 | $0.170 | 2,608,600 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.170 | $0.170 | 1,722,700 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.170 | $0.170 | 1,452,700 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.170 | $0.160 | 3,331,500 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.170 | $0.170 | 2,049,000 | |
| $0.170 | -0.020 | -10.5% | $0.190 | $0.200 | $0.170 | 18,376,200 | |
| $0.190 | +0.010 | +5.6% | $0.180 | $0.230 | $0.180 | 10,430,800 | |
| $0.180 | +0.010 | +5.9% | $0.170 | $0.180 | $0.170 | 2,417,600 | |
| $0.170 | -0.004 | -2.2% | $0.170 | $0.180 | $0.170 | 1,262,400 | |
| $0.174 | +0.001 | +0.8% | $0.175 | $0.175 | $0.166 | 1,936,134 | |
| $0.173 | +0.002 | +1.5% | $0.170 | $0.177 | $0.166 | 5,231,098 | |
| $0.170 | 0.000 | 0.0% | $0.170 | $0.180 | $0.160 | 3,194,500 | |
| $0.170 | -0.010 | -5.6% | $0.180 | $0.180 | $0.170 | 2,217,000 |
Splits
2 splits since 2007 · OTC:NWBO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-16 | Consolidation | |
| 1-for-15 | Consolidation |
- Ticker
- OTC:NWBO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 26, 2026
Northwest Biotherapeutics Announces Expansion of Its Technical Team
Latest deck · Jul 3, 2026
Shareholder Meeting (July 2026)
Shareholder meeting · 18 slides
Latest news
Northwest Biotherapeutics Announces Expansion of Its Technical Team
Oct 26, 2026
Closed $0.17 (+13.3%) on Oct 26, 2026
Northwest Biotherapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in the last 12 months · 3 in all · newest Oct 26, 2026 · oldest 2026
- Decks
- 15 decks · latest Jul 3, 2026
Valuation
EV/sales 99.4× against a median of 1.3×: 4th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $283.8M USD
- P/E
- Loss
- EV/sales
- 99.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.90
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Northwest Biotherapeutics, Inc. · OTC:NWBO | US$220.0M | US$283.8M | n/a | 99.4× | n/a | n/a | n/a | n/a | 0.90 |
| Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA | US$222.2M | US$82.43M | n/a | 1.3× | n/a | 2.8× | −108.3% | 0.7× | 1.11 |
| Clover Biopharmaceuticals Ltd. · HKEX:2197 | US$222.0M | US$206.5M | n/a | 403× | n/a | n/a | n/a | n/a | n/a |
| Aprilbio Co., Ltd. · KRX:397030 | US$221.1M | US$161.1M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | n/a |
| Keros Therapeutics, Inc. · NASDAQ:KROS | US$219.7M | −US$24.67M | n/a | −0.6× | n/a | 0.8× | −152.7% | 0.1× | 1.16 |
| Immuneering Corporation · NASDAQ:IMRX | US$218.7M | US$160.5M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.17 |
| Allogene Therapeutics, Inc. · NASDAQ:ALLO | US$217.5M | −US$7.44M | n/a | −1.6× | n/a | 0.6× | n/a | 0.2× | 1.93 |
| ProKidney Corp. · NASDAQ:PROK | US$217.3M | US$77.56M | n/a | 100× | n/a | n/a | n/a | n/a | 1.61 |
| Pyxis Oncology, Inc. · NASDAQ:PYXS | US$216.5M | US$160.9M | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 0.89 |
| Oryzon Genomics SA · BME:ORY | US$216.4M | US$206.7M | n/a | n/a | n/a | 1.6× | n/a | 0.1× | n/a |
| Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT | US$214.1M | −US$25.02M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.72 |
| Median of the others | US$218.1M | US$121.4M | 1.3× | 1.5× | −130.5% | 0.1× | 1.17 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.050 · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Linda F. Powers | Chief Executive Officer |
| Alton L. Boynton | Chief Scientific Officer |
| Marnix L. Bosch | Ph.D. Chief Technical Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 13, 2026 · After close | 0.0% |
| Q3 2025 | Nov 14, 2025 · After close | −4.2% |
| Q2 2025 | Aug 14, 2025 | +4.2% |
| Q1 2025 | May 8, 2025 · After close | +3.7% |
| Q4 2024 | Mar 31, 2025 | −8.7% |
| Q3 2024 | Nov 7, 2024 · After close | +15.4% |
| Q2 2024 | Aug 9, 2024 · After close | 0.0% |
| Q1 2024 | May 10, 2024 · After close | 0.0% |
| Q4 2023 | Mar 5, 2024 · After close | +3.6% |
| Q3 2023 | Nov 9, 2023 · After close | +1.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 9, 2023 · After close | +2.0% |
| Q1 2023 | May 10, 2023 · After close | +3.5% |
| Q4 2022 | Feb 28, 2023 · After close | 0.0% |
| Q3 2022 | Nov 9, 2022 · After close | +2.9% |
| Q2 2022 | Aug 9, 2022 · After close | +1.5% |
| Q1 2022 | May 19, 2022 | −1.4% |
| Q4 2021 | Mar 2, 2022 | −6.7% |
| Quarter to Sep 30, 2021 | Nov 18, 2021 | −8.9% |
| Quarter to Jun 30, 2021 | Aug 13, 2021 | −2.4% |
| Quarter to Mar 31, 2021 | May 20, 2021 | +3.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (July 2026) | Shareholder meeting | 18 slides | Jul 3, 2026 |
| Technical Presentation (June 2025) | Technical | 14 slides | June 2025 |
| ASCO 2023 | Conference | 44 slides | Jun 3, 2023 |
| Glioblastoma Drug Development Summit 2023 | Conference | 33 slides | Mar 15, 2023 |
| Glioblastoma Drug Development Summit 2023 | Conference | 33 slides | Mar 15, 2023 |
| Technical Presentation (February 2021) | Technical | 30 slides | February 2021 |
| ASCO 2019 | Conference | 35 slides | Jun 2, 2019 |
| Phacilitate Conference 2019 | Conference | 26 slides | Jan 23, 2019 |
| I-O Summit 2018 | Conference | 21 slides | Aug 29, 2018 |
| Investor Presentation (August 2017) | Investor deck | 31 slides | Aug 31, 2017 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 2nd Immunotherapy of Cancer Conference (ITOC-2) 2015 | Conference | 15 slides | Mar 30, 2015 |
| Brain Tumor Biotech Summit 2013 | Conference | 24 slides | Jun 7, 2013 |
| Big CEOs Investor Conference 2013 | Conference | 27 slides | Feb 11, 2013 |
| Investor Presentation (January 2013) | Investor deck | 29 slides | January 2013 |
| IPO Roadshow (November 2012) | IPO roadshow | 31 slides | Nov 2, 2012 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.38M | 1.38M | 1.93M | 1.68M | 1.00M | 1.29M | 2.41M | 412.0K | 336.0K | 623.0K |
| Research and development | 28.8M | 34.9M | 27.7M | 35.5M | 20.3M | 33.6M | 14.1M | 18.2M | 33.5M | 60.1M |
| Operating income | -59.9M | -66.5M | -55.5M | -67.2M | -52.7M | -86.6M | -28.0M | -41.5M | -54.7M | -79.3M |
| Depreciation and amortization | 2.06M | 1.74M | 1.52M | 1.25M | 324.0K | 87.0K | 21.0K | 1.29M | 439.0K | 189.0K |
| EBITDA | -57.9M | -64.8M | -54.0M | -65.9M | -52.4M | -86.5M | -28.0M | -40.2M | -54.2M | -79.1M |
| Interest expense | 8.70M | 7.77M | 5.24M | 6.07M | 5.01M | 8.54M | 2.98M | 9.87M | 5.54M | 3.82M |
| Income before tax | -60.7M | -83.8M | ||||||||
| Income tax | -537.0K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -60.2M | -83.8M | -62.6M | -105.0M | 179.1M | -529.8M | -20.8M | -35.8M | -73.1M | -80.2M |
| Earnings per share, basic | -0.04 | -0.07 | -0.06 | -0.10 | 0.21 | -0.73 | -0.04 | -0.12 | -0.31 | -0.77 |
| Earnings per share, diluted | -0.04 | -0.07 | -0.06 | -0.10 | -0.06 | -0.73 | -0.04 | -0.12 | -0.31 | -0.77 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.04M | 2.17M | 2.13M | 6.96M | 15.2M | 9.98M | 372.0K | 22.2M | 117.0K | 6.87M |
| Current assets | 5.52M | 4.06M | 4.13M | 9.43M | 17.3M | 15.5M | 3.20M | 23.8M | 1.40M | 7.88M |
| Property, plant and equipment | 17.4M | 16.2M | 17.3M | 13.4M | 15.0M | 1.04M | 281.0K | 108.0K | 47.5M | 315.0K |
| Goodwill | 626.0K | 626.0K | 626.0K | 626.0K | 626.0K | 626.0K | 0 | |||
| Total assets | 81.3M | 26.7M | 27.9M | 31.3M | 40.2M | 32.9M | 10.6M | 24.7M | 48.9M | 52.9M |
| Accounts payable | 12.4M | |||||||||
| Current liabilities | 91.7M | 68.3M | 45.2M | 126.0M | 133.8M | 382.4M | 44.2M | 69.8M | 87.7M | 76.4M |
| Total debt | 60.0M | 62.7M | 40.8M | 21.5M | 32.4M | 14.8M | 12.7M | 16.8M | 31.4M | 31.7M |
| Total liabilities | 128.9M | 105.7M | 74.9M | 136.4M | 164.2M | 395.8M | 55.7M | 71.8M | 96.2M | 79.4M |
| Shareholders' equity | -60.3M | -94.5M | -65.8M | -128.1M | -124.0M | -362.9M | -45.1M | -48.1M | -67.3M | -26.5M |
| Shares outstanding | 1.56B | 1.33B | 1.18B | 1.07B | 948.4M | 829.6M | 614.3M | 523.2M | 328.9M | 157.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -44.8M | -57.0M | -53.6M | -52.8M | -38.3M | -32.1M | -31.9M | -34.6M | -36.5M | -55.7M |
| Capital spending | -1.50M | -1.01M | -171.0K | |||||||
| Free cash flow | -46.3M | -58.0M | -32.0M | |||||||
| Cash from investing | -1.81M | -1.01M | -3.44M | -2.90M | -6.01M | -8.14M | -360.0K | 45.4M | 212.0K | -4.94M |
| Cash from financing | 49.3M | 56.8M | 52.8M | 42.0M | 48.1M | 52.7M | 9.95M | 7.87M | 34.3M | 38.3M |
| Change in cash | 865.0K | 49.0K | -4.84M | -8.20M | 5.19M | 9.61M | -21.9M | 22.1M | -6.75M | -16.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jul 31, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 17, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Apr 21, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 16, 2026 | Offer document | SEC |
| 10-K · Annual report | Apr 15, 2026 | Annual report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Apr 7, 2026 | Acquisition or disposal | SEC |
| NT 10-K · Late filing notice | Mar 31, 2026 | Explanation request | SEC |
| 8-K · Current report | Jan 15, 2026 | Current report | SEC |
| 8-K · Current report | Jan 2, 2026 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Nov 28, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Nov 26, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Nov 25, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 24, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 20, 2025 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Nov 19, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 31, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 30, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 24, 2025 | Current report | SEC |
| S-3 · Registration statement | Oct 23, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 424B5 · Prospectus | Jul 1, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 424B5 · Prospectus | Dec 26, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 26, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 1, 2024 | Material contract | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 2, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 3, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 25, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jun 4, 2024 | Material contract | SEC |
| DEF 14A · Proxy statement | Jun 3, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 22, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 2, 2024 | Material contract | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 22, 2024 | Management or board change | SEC |
| 8-K · Current report | Mar 14, 2024 | Management or board change | SEC |
| 10-K · Annual report | Mar 5, 2024 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 1, 2024 | Explanation request | SEC |
| 4 · Change in ownership | Dec 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 16, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 10, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Mar 8, 2023 | Material contract | SEC |
| 10-K · Annual report | Feb 28, 2023 | Annual report | SEC |
| 5 · Annual statement of ownership | Feb 7, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2023 | Current report | SEC |
| 8-K · Current report | Jan 6, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Dec 23, 2022 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Dec 16, 2022 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 5, 2022 | Insider trade | SEC |
| DEF 14A · Proxy statement | Dec 5, 2022 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Nov 25, 2022 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2022 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Oct 26, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 24, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 21, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 21, 2022 | Other filings | SEC |
| S-3 · Registration statement | Oct 18, 2022 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 9, 2022 | Quarterly report | SEC |
| 8-K · Current report | Jul 26, 2022 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jul 14, 2022 | Other filings | SEC |
| 10-K/A · Annual report, amended | Jun 30, 2022 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Jun 28, 2022 | Other filings | SEC |
| 10-Q · Quarterly report | May 9, 2022 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | May 2, 2022 | Annual report | SEC |
| 10-K · Annual report | Mar 1, 2022 | Annual report | SEC |
| 8-K · Current report | Nov 29, 2021 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 15, 2021 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 16, 2021 | Quarterly report | SEC |
| 8-K · Current report | May 24, 2021 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 17, 2021 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Apr 16, 2021 | Meeting notice | SEC |
| 10-K · Annual report | Mar 31, 2021 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2021 | Material contract | SEC |
| 8-K · Current report | Jan 26, 2021 | Current report | SEC |
| 4 · Change in ownership | Jan 19, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | Jan 15, 2021 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 10, 2020 | Explanation request | SEC |
| 8-K · Current report | Nov 2, 2020 | Current report | SEC |
| 4 · Change in ownership | Oct 16, 2020 | Insider trade | SEC |
| 424B5 · Prospectus | Oct 13, 2020 | Offer document | SEC |
| 8-K/A · Current report, amended | Sep 15, 2020 | Meeting outcome | SEC |
| D | Sep 14, 2020 | Other filings | SEC |
| 8-K · Current report | Sep 1, 2020 | Acquisition or disposal | SEC |
| 8-K · Current report | Aug 20, 2020 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 10, 2020 | Quarterly report | SEC |
| 424B5 · Prospectus | Aug 7, 2020 | Offer document | SEC |
| 4 · Change in ownership | Jul 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2020 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 26, 2020 | Offer document | SEC |
| 10-Q · Quarterly report | Jun 23, 2020 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jun 23, 2020 | Annual report | SEC |
| 424B5 · Prospectus | Jun 12, 2020 | Offer document | SEC |
| 8-K · Current report | Jun 8, 2020 | Management or board change | SEC |
| 8-K · Current report | Jun 4, 2020 | Management or board change | SEC |
| 424B5 · Prospectus | May 29, 2020 | Offer document | SEC |
| 8-K · Current report | May 27, 2020 | Material contract | SEC |
| 8-K · Current report | May 20, 2020 | Current report | SEC |
| NT 10-Q · Late filing notice | May 12, 2020 | Explanation request | SEC |
| 4 · Change in ownership | May 1, 2020 | Insider trade | SEC |
| 8-K · Current report | Apr 23, 2020 | Meeting outcome | SEC |
| 424B5 · Prospectus | Apr 9, 2020 | Offer document | SEC |
| 8-K · Current report | Apr 1, 2020 | Material contract | SEC |
| DEF 14A · Proxy statement | Mar 27, 2020 | Meeting notice | SEC |
| 10-K · Annual report | Mar 16, 2020 | Annual report | SEC |
| 424B5 · Prospectus | Feb 24, 2020 | Offer document | SEC |
| 4 · Change in ownership | Feb 5, 2020 | Insider trade | SEC |
| 424B5 · Prospectus | Jan 15, 2020 | Offer document | SEC |
| 424B5 · Prospectus | Jan 3, 2020 | Offer document | SEC |
| 3 · Initial statement of ownership | Dec 20, 2019 | Insider trade | SEC |
| 8-K · Current report | Dec 13, 2019 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 12, 2019 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Nov 1, 2019 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 29, 2019 | Other filings | SEC |
| 424B5 · Prospectus | Oct 28, 2019 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Oct 28, 2019 | Other filings | SEC |
| 424B5 · Prospectus | Oct 18, 2019 | Offer document | SEC |
| S-3 · Registration statement | Oct 18, 2019 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 9, 2019 | Quarterly report | SEC |
| 8-K · Current report | Jul 22, 2019 | Financing | SEC |
| 424B5 · Prospectus | Jul 17, 2019 | Offer document | SEC |
| 424B5 · Prospectus | Jul 17, 2019 | Offer document | SEC |
| 8-K · Current report | May 28, 2019 | Material contract | SEC |
| 10-Q · Quarterly report | May 10, 2019 | Quarterly report | SEC |
| 10-K · Annual report | Apr 2, 2019 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 19, 2019 | Explanation request | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2019 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2019 | Big-stake notice | SEC |
| 8-K · Current report | Feb 7, 2019 | Meeting outcome | SEC |
| 4 · Change in ownership | Jan 29, 2019 | Insider trade | SEC |
| DEF 14A · Proxy statement | Jan 7, 2019 | Meeting notice | SEC |
| 8-K · Current report | Dec 20, 2018 | Acquisition or disposal | SEC |
| 8-K · Current report | Dec 11, 2018 | Material contract | SEC |
| 8-K · Current report | Nov 28, 2018 | Current report | SEC |
| 8-K · Current report | Nov 23, 2018 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 16, 2018 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 15, 2018 | Explanation request | SEC |
| 8-K · Current report | Nov 13, 2018 | Material contract | SEC |
| 8-K · Current report | Sep 13, 2018 | Financing | SEC |
| 10-Q · Quarterly report | Aug 14, 2018 | Quarterly report | SEC |
| 8-K · Current report | Jun 28, 2018 | Current report | SEC |
| 424B5 · Prospectus | Jun 28, 2018 | Offer document | SEC |
| 4 · Change in ownership | Jun 18, 2018 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2018 | Financing | SEC |
| 8-K · Current report | Jun 1, 2018 | Management or board change | SEC |
| 8-K · Current report | May 31, 2018 | Financing | SEC |
| 4 · Change in ownership | May 31, 2018 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2018 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2018 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2018 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2018 | Insider trade | SEC |
| 8-K · Current report | May 21, 2018 | Financing | SEC |
| 10-Q · Quarterly report | May 16, 2018 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 16, 2018 | Explanation request | SEC |
| 8-K · Current report | May 7, 2018 | Material contract | SEC |
| 8-K · Current report | May 2, 2018 | Meeting outcome | SEC |
| 10-K · Annual report | Apr 17, 2018 | Annual report | SEC |
| DEFR14A | Apr 12, 2018 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 9, 2018 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 6, 2018 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 4, 2018 | Other filings | SEC |
| PRER14A | Apr 4, 2018 | Other filings | SEC |
| NT 10-K · Late filing notice | Apr 2, 2018 | Explanation request | SEC |
| UPLOAD · Letter from the SEC | Apr 2, 2018 | Other filings | SEC |
| 424B5 · Prospectus | Mar 26, 2018 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Mar 26, 2018 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Mar 22, 2018 | Insider trade | SEC |
| 8-K · Current report | Mar 22, 2018 | Current report | SEC |
| 4 · Change in ownership | Mar 21, 2018 | Insider trade | SEC |
| 8-K · Current report | Mar 20, 2018 | Material contract | SEC |
| 8-K · Current report | Mar 15, 2018 | Financing | SEC |
| 4 · Change in ownership | Mar 14, 2018 | Insider trade | SEC |
| 8-K · Current report | Mar 7, 2018 | Financing | SEC |
| 8-K · Current report | Mar 2, 2018 | Management or board change | SEC |
| 8-K · Current report | Feb 21, 2018 | Financing | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2018 | Big-stake notice | SEC |
This page holds 200 of 804 filings. Open Filings
Cap table
Built by 6ix from Northwest Biotherapeutics, Inc.’s releases
- Common shares
- 1,705,637,993
- Fully diluted
- 1,705,637,993
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,705,637,993 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,705,637,993 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Susan B Bayh Other companies: Dendreon Corp (Director · Dec 6, 2006 – Jan 3, 2014 · Past); Curis, Inc. (Director · Jun 1, 2006 – Jan 17, 2013 · Past); Dyax Corp (Director · May 18, 2006 – May 6, 2010 · Past); Elevance Health, Inc. (Director · Feb 3, 2006 – May 21, 2012 · Past) | Director · Jan 25, 2016 – Jan 25, 2016 · Past |
| Jerry J Jasinowski Other companies: Timken Company (the) (Director · Feb 6, 2006 – May 11, 2010 · Past); Webmethods Inc (Director · Jan 3, 2006 – May 29, 2007 · Past); The Phoenix Companies Inc (Director · Oct 3, 2005 – Apr 1, 2009 · Past) | Director · Apr 30, 2015 – Dec 1, 2022 · Past |
| Alton L. Boynton | Chief Scientific Officer · Since at least May 17, 2006 |
| Anthony P Deasey | Senior VP of Finance - CFO, Director · Oct 1, 2007 – Oct 1, 2007 · Past |
| Cofer Black | Director · May 28, 2018 – May 28, 2018 · Past |
| Jean M Davis | See Remarks · Dec 9, 2019 – Dec 9, 2019 · Past |
| Leslie J Goldman | See Remarks · Jul 2, 2020 – Jul 2, 2020 · Past |
| Linda F. Powers | Chief Executive Officer · Since at least Oct 8, 2026 |
| Marnix L. Bosch | Ph.D. Chief Technical Officer · Since at least Apr 3, 2023 |
| Navid Malik | Director · Apr 30, 2015 – Jul 26, 2024 · Past |
All 11 people
| Person | Seat |
|---|---|
| Robert A Farmer | Director · Apr 30, 2015 – Apr 30, 2015 · Past |
Log in to ask 6ix AI your own questions about Northwest Biotherapeutics, Inc.